Trial reportLipids in health and disease2026
Association between egg-derived phosphatidylcholine intake and trimethylamine N-oxide in healthy middle-aged and older adults.
Trial report in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEgg-derived phosphatidylcholine may support the maintenance of cognitive function. However, its metabolite trimethylamine N-oxide is considered a potential cardiovascular risk factor. The present study aimed to assess, for the first time, the effects of long-term intake of egg-derived phosphatidylcholine on serum trimethylamine N-oxide concentrations in healthy Japanese middle-aged and older adults.
methodsA secondary analysis was conducted using preserved serum samples obtained from a previous randomized controlled trial (UMIN000041554). The study population, comprising thirty-two healthy middle-aged and older Japanese adults, was categorized into four groups based on their level of phosphatidylcholine intake: placebo (0 g/day), low-dose (0.3 g/day), medium-dose (1.0 g/day), and high-dose (3.0 g/day). Serum trimethylamine N-oxide concentrations were measured before and after the 12-week intervention.
resultsIn the high-dose phosphatidylcholine group, serum trimethylamine N-oxide concentration increased significantly at 12 weeks (Week 12) compared with Baseline (Week 0) (P = 0.028). In contrast, no significant between-group differences were observed in serum trimethylamine N-oxide concentrations or in the magnitude of change from Baseline to Week 12, including comparisons with placebo. Across all groups, mean trimethylamine N-oxide values remained substantially below the threshold associated with high clinical risk.
conclusionsTwelve weeks of egg-derived phosphatidylcholine supplementation did not result in serum trimethylamine N-oxide concentrations approaching clinically concerning levels under the specific conditions tested. These findings suggest that egg-derived phosphatidylcholine may serve as a dietary source of choline without inducing a substantial elevation in trimethylamine N-oxide in healthy middle-aged and older adults. Confirmation of these results in studies with larger sample sizes is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.